Cytokinetics CYTK Return on equity
Discontinued — last reported Q2 '22
Return on equity at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
Based on trailing twelve months.
The official record: Cytokinetics’s 10-Q, filed August 5, 2022, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's return on equity?
- Cytokinetics (CYTK) reported return on equity of -337.6% in Q2 2022.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.